Abstract
Background: Conditionally replicative adenoviruses (CRAds) are widely studied tools for cancer gene therapy. The utility of CRAds is based on their ability to destroy tumor by oncolysis. Unfortunately, systemic adenoviral delivery into tumors and metastases is currently inefficient due to liver sequestration of intravenous virus and a neutralizing antibody response that hinders readministration. One potential solution for improving tumor targeting might be to engineer cells as viral carriers, thereby combining cellular tropism for tumors with the oncolytic effect provided by CRAds.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
